HER2 is an effective therapeutic target in breast cancer, and although HER2 expression does not appear to be associated with osteotropism, clinical trials have demonstrated the efficacy of HER2 inhibitors in delaying skeletal events [94]. The gene discussed is ERBB2; the disease is breast cancer.